Interleukin 22 and 6 serum concentrations decrease
under long-term biologic therapy in psoriasis

Irmina Olejniczak-Staruch; Joanna Narbutt; Igor Bednarski; Anna Woźniacka; Joanna Sieniawska; Marzena Kraska-Gacka; Janusz Śmigielski; Aleksandra Lesiak

doi:10.5114/ada.2020.100481

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2020
vol. 37

Send email

Copy url:

abstract:

Original paper

Interleukin 22 and 6 serum concentrations decrease under long-term biologic therapy in psoriasis

Irmina Olejniczak-Staruch

¹

,

Joanna Narbutt

²

,

Igor Bednarski

²

,

Anna Woźniacka

¹

,

Joanna Sieniawska

¹

,

Marzena Kraska-Gacka

¹

,

Janusz Śmigielski

³

,

Aleksandra Lesiak

²

Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland
State Higher Vocational School, Konin, Poland

Adv Dermatol Allergol 2020; XXXVII (5): 705-711

DOI: https://doi.org/10.5114/ada.2020.100481

Online publish date: 2020/11/07

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Olejniczak-Staruch I, Narbutt J, Bednarski I, et al. Interleukin 22 and 6 serum concentrations decrease
under long-term biologic therapy in psoriasis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(5):705-711. doi:10.5114/ada.2020.100481.

APA

Olejniczak-Staruch, I., Narbutt, J., Bednarski, I., Woźniacka, A., Sieniawska, J.,  & Kraska-Gacka, M. et al. (2020). Interleukin 22 and 6 serum concentrations decrease
under long-term biologic therapy in psoriasis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(5), 705-711. https://doi.org/10.5114/ada.2020.100481

Chicago

Olejniczak-Staruch, Irmina, Joanna Narbutt, Igor Bednarski, Anna Woźniacka, Joanna Sieniawska, Marzena Kraska-Gacka,  and Janusz Śmigielski et al. 2020. "Interleukin 22 and 6 serum concentrations decrease
under long-term biologic therapy in psoriasis". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 37 (5): 705-711. doi:10.5114/ada.2020.100481.

Harvard

Olejniczak-Staruch, I., Narbutt, J., Bednarski, I., Woźniacka, A., Sieniawska, J., Kraska-Gacka, M., Śmigielski, J.,  and Lesiak, A. (2020). Interleukin 22 and 6 serum concentrations decrease
under long-term biologic therapy in psoriasis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(5), pp.705-711. https://doi.org/10.5114/ada.2020.100481

MLA

Olejniczak-Staruch, Irmina et al. "Interleukin 22 and 6 serum concentrations decrease
under long-term biologic therapy in psoriasis." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 37, no. 5, 2020, pp. 705-711. doi:10.5114/ada.2020.100481.

Vancouver

Olejniczak-Staruch I, Narbutt J, Bednarski I, Woźniacka A, Sieniawska J, Kraska-Gacka M et al. Interleukin 22 and 6 serum concentrations decrease
under long-term biologic therapy in psoriasis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(5):705-711. doi:10.5114/ada.2020.100481.

Introduction
Psoriasis, affecting approximately 2% of the worldwide population, is a chronic, inflammatory skin disease in which overexpression of proinflammatory cytokines is observed. Most of the available data on the influence of antipsoriatic therapy on the cytokine serum concentration are inconsistent and based on short-term observations.

Aim
To evaluate the influence of long-term biologic therapy with tumor necrosis factor a (TNF-a) blockers (adalimumab, etanercept, infliximab) and IL-12/23 inhibitor (ustekinumab) on the level of IL-6, IL-22 in the sera of patients with psoriasis.

Material and methods
Blood samples were collected from 42 psoriatic patients in order to determine IL-6 and IL-22 serum concentrations prior to and at the 3rd, 12th, 24th and 36th month of biologic therapy. Psoriasis Activity and Severity Index (PASI) was assessed at the same time points. The control group consisted of 30 sex- and age-matched healthy volunteers.

Results
Mean PASI index at baseline was 14.49 ±3.69 and decreased significantly until the end of the observation. Mean IL-6 serum concentration decreased significantly in all study groups (p < 0.05). A statistically significant decrease in IL-22 concentrations was demonstrated during the treatment with adalimumab and infliximab but not etanercept or ustekinumab.

Conclusions
According to obtained results, IL-6 and IL-22 serum concentration may be an accurate marker of response to antipsoriatic therapy, even though not correlated with PASI index. Biologic therapy in psoriasis allows for long-term clinical improvement expressed not only by the remission of skin lesions, but also by lowering serum concentrations of pro-inflammatory interleukins.

keywords:

Interleukin 22 and 6 serum concentrations decrease under long-term biologic therapy in psoriasis

Irmina Olejniczak-Staruch 1 , Joanna Narbutt 2 , Igor Bednarski 2 , Anna Woźniacka 1 , Joanna Sieniawska 1 , Marzena Kraska-Gacka 1 , Janusz Śmigielski 3 , Aleksandra Lesiak 2

interleukin 22, interleukin 6, psoriasis, biologic therapy

Irmina Olejniczak-Staruch

¹

,

Joanna Narbutt

²

,

Igor Bednarski

²

,

Anna Woźniacka

¹

,

Joanna Sieniawska

¹

,

Marzena Kraska-Gacka

¹

,

Janusz Śmigielski

³

,

Aleksandra Lesiak

²